抗生素
幽门螺杆菌
生物
抗生素耐药性
人类病原体
抗菌剂
背景(考古学)
药物发现
病菌
微生物学
抗药性
细菌
生物信息学
遗传学
古生物学
作者
Nicole A Vita,Shelby M Anderson,Michael D LaFleur,Richard E Lee
标识
DOI:10.1016/j.mib.2022.102203
摘要
Helicobacter pylori is an important human pathogen with increasing antimicrobial resistance to standard-of-care antibiotics. Treatment generally includes a combination of classical broad-spectrum antibiotics and a proton-pump inhibitor, which often leads to perturbation of the gut microbiome and the potential for the development of antibiotic resistance. In this review, we examine reports, primarily from the past decade, on the discovery of new anti-H. pylori therapeutics, including approaches to develop narrow-spectrum and mechanistically unique antibiotics to treat these infections in their gastric niche. Compound series that target urease, respiratory complex I, and menaquinone biosynthesis are discussed in this context, along with bivalent antibiotic approaches that suppress resistance development. With increases in the understanding of the unique physiology of H. pylori and technological advances in the field of antibacterial drug discovery, there is a clear promise that novel therapeutics can be developed to effectively treat H. pylori infections.
科研通智能强力驱动
Strongly Powered by AbleSci AI